Jeanette Lundin

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: CANCERS. 2024;16(22):3821
A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL)
Zhong W; Kokhaei P; Mulder TA; Ghaderi A; Moshfegh A; Lundin J; Palma M; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: LEUKEMIA RESEARCH. 2022;122:106945
Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study
Ma S; Rosen ST; Winqvist M; Frankfurt O; Winter JN; Gordon L; Helenowski I; Zhang H; Kreutzer J; Sonnert-Husa S; Osterborg A; Lundin J
Article: EJHAEM. 2021;2(3):525-529
Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia
Lundin J; Mulder TA; Kattstrom M; Wasterlid T; Uddevik A; Mellstedt H; Heimersson K; Hansson L; Palma M; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;191(3):426-432
Risk-adapted bendamustine plus rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients
Mattsson A; Sylvan SE; Asklid A; Wiggh J; Winqvist M; Lundin J; Mansouri L; Rosenquist R; Johansson H; Osterborg A; Hansson L
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2020;476:112675
Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies
Stasilojc G; Felberg A; Urban A; Kowalska D; Ma S; Blom AM; Lundin J; Osterborg A; Okroj M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;183(2):212-224
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes
Palma M; Krstic A; Perez LP; Bergloef A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Hoeglund P; Kimby E; OEsterborg A; Mansson R; Smith CIE
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2017;66(1):91-102
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
Winqvist M; Mozaffari F; Palma M; Sylvan SE; Hansson L; Mellstedt H; Osterborg A; Lundin J
Article: HAEMATOLOGICA. 2016;101(12):1573-1580
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Osterborg A
Article: ANNALS OF HEMATOLOGY. 2014;93(10):1725-1733
Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients
Sylvan SE; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Article: LEUKEMIA AND LYMPHOMA. 2014;55(8):1774-1780
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region
Sylvan SE; Hansson L; Karlsson C; Norin S; Lundin J; Osterborg A
Article: PLOS ONE. 2013;8(10):e78339
The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.
Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
Article: HAEMATOLOGICA. 2011;96(8):1161-1169
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia
Gunnarsson R; Mansouri L; Isaksson A; Goransson H; Cahill N; Jansson M; Rasmussen M; Lundin J; Norin S; Buhl AM; Smedby KE; Hjalgrim H; Karlsson K; Jurlander J; Geisler C; Juliusson G; Rosenquist R
Article: MEDICAL ONCOLOGY. 2010;27(3):820-825
Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia
Norin S; Kimby E; Lundin J
Article: LEUKEMIA RESEARCH. 2010;34(3):335-339
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia
Kaderi MA; Mansouri M; Zainuddin N; Cahill N; Gunnarsson R; Jansson M; Kimby E; Aleskog A; Lundin J; Glimelius B; Melbye M; Juliusson G; Jurlander J; Rosenquist R
Article: CELL DEATH AND DIFFERENTIATION. 2009;16(7):1018-1029
Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy
Laane E; Tamm KP; Buentke E; Ito K; Kharaziha P; Oscarsson J; Corcoran M; Bjorklund A-C; Hultenby K; Lundin J; Heyman M; Soderhall S; Mazur J; Porwit A; Pandolfi PP; Zhivotovsky B; Panaretakis T; Grander D
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2009;144(1):78-85
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia
Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Article: CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY. 2007;72B(6):450-457
Performance of calibration standards for antigen quantitation with flow cytometry chronic lymphocytic leukemia
Rossmann ED; Lenkei R; Lundin J; Mellstedt H; Oesterborg A
Article: LEUKEMIA. 2007;21(4):627-632
Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies:: a randomized multicenter study
Hedenus M; Birgegard G; Nasman P; Ahlberg L; Karlsson T; Lauri B; Lundin J; Larfars G; Osterborg A
Article: LEUKEMIA. 2007;21(3):511-514
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody)
Karlsson C; Hansson L; Celsing F; Lundin J
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;135(4):475-485
Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia
Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Article: LEUKEMIA AND LYMPHOMA. 2006;47(7):1229-1238
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia:: long-term effects of fludarabine and alemtuzumab treatment
Kiaii S; Choudhury A; Mozaffari F; Rezvany R; Lundin J; Mellstedt H; Osterborg A
Article: LEUKEMIA. 2004;18(11):1810-1815
Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL
Kokhaei P; Choudhury A; Mahdian R; Lundin J; Moshfegh A; Österborg A; Mellstedt H
Article: BLOOD. 2004;104(4):948-955
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
Hale G; Rebello P; Brettman LR; Fegan C; Kennedy B; Kimby E; Leach M; Lundin J; Mellstedt H; Moreton P; Rawstron AC; Waldmann H; Osterborg A; Hillmen P
Article: SEMINARS IN HEMATOLOGY. 2004;41(3):234-245
Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia
Lundin J; Österborg A
Article: BLOOD. 2004;103(8):2920-2924
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
Enblad G; Hagberg H; Erlanson M; Lundin J; MacDonald AP; Repp R; Schetelig J; Seipelt G; Österborg A
Article: LEUKEMIA. 2004;18(3):484-490
Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Österborg A; Mellstedt H
Article: BLOOD. 2003;101(11):4267-4272
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
Lundin J; Hagberg H; Repp R; Cavallin-Stahl E; Fredén S; Juliusson G; Rosenblad E; Tjonnfjord G; Wiklund T; Österborg A
Article: HEMATOLOGY JOURNAL. 2003;4(4):248-252
Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.
Lundin J; Osterborg A; Björkholm M; Björkstrand B; Celsing F; Hjalmar V; Linder O; Luthman M; Merup M; Tidefelt U; Mellstedt H; Myeloma Group of Central Sweden
Article: BLOOD. 2002;100(3):768-773
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Österborg A
Article: MEDICAL ONCOLOGY. 2002;19(4):277-280
Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia
Cavalli-Björkman N; Ösby E; Lundin J; Kalin M; Österborg A; Gruber A
Article: HEMATOLOGY JOURNAL. 2001;2(5):300-306
Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies.
Rossmann ED; Lundin J; Lenkei R; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;112(1):155-160
Interleukin 4 therapy for patients with chronic lymphocytic leukaemia:: a phase I/II study
Lundin J; Kimby E; Bergmann L; Karakas T; Mellstedt H; Österborg A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1999;63(3):163-170
The influence of interferon-α on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma
Hassan M; Nilsson C; Olsson H; Lundin J; Österborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 1998;16(10):3257-3263
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas:: A phase II multicenter study
Lundin J; Österborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;58(1):5-13
Clonal CD8(+) and CD52(-) T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52)
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Visa fler

Alla övriga publikationer

Letter: HAEMATOLOGICA. 2022;107(4):1000-1003
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial
Blixt L; Wullimann D; Aleman S; Lundin J; Chen P; Gao Y; Cuapio A; Akber M; Lange J; Rivera-Ballesteros O; Buggert M; Ljunggren H-G; Hansson L; Osterborg A
Letter: HAEMATOLOGICA. 2019;104(5):E208-E210
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
Winqvist M; Andersson P-O; Asklid A; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Rosenquist R; Spath F; Hansson L; Osterborg A
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2018;182(4):590-594
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study
Winqvist M; Palma M; Heimersson K; Mellstedt H; OEsterborg A; Lundin J
Meeting abstract: BLOOD. 2016;128(22):3235
Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients
Palma M; Krstic A; Berglof A; Wang Q; Blomberg E; Meinke S; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; Kimby E; Hoglund P; Mansson R; Osterborg A; Smith E
Meeting abstract: BLOOD. 2015;126(23):1745
Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program
Hansson L; Winqvist M; Asklid A; Andersson P-O; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Osterborg A
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2012;159(5):608-612
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression
Sylvan SE; Rossmann E; Mozaffari F; Porwit A; Norin S; Karlsson C; Hansson L; Lundin J; Osterborg A
Letter: BLOOD CANCER JOURNAL. 2011;1(6):e22
Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia
Karlsson C; Dahl H; Lundin J; Rossmann E; Brytting M; Mellstedt H; Linde A; Osterborg A
Letter: LEUKEMIA. 2010;24(1):211-215
Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients
Gunnarsson R; Isaksson A; Mansouri M; Goransson H; Jansson M; Cahill N; Rasmussen M; Staaf J; Lundin J; Norin S; Buhl AM; Smedby KE; Hjalgrim H; Karlsson K; Jurlander J; Juliusson G; Rosenquist R
Review: CURRENT HEMATOLOGIC MALIGNANCY REPORTS. 2009;4(1):47-53
Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Osterborg A; Karlsson C; Lundin J
Corrigendum: LEUKEMIA. 2008;22(2):462
Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies:: a randomized multicenter study (vol 21, pg 627, 2007)
Hedenus M; Birgegard G; Nasman P; Ahlberg L; Karlsson T; Lauri B; Lundin J; Larfars G; Osterborg A
Letter: LEUKEMIA. 2007;21(8):1821
Reply to 'Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia' by Dr Laurenti et al.
Lundin J
Letter: LEUKEMIA. 2006;20(12):2204-2007
Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia:: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation
Karlsson C; Norin S; Kimby E; Sander B; MacDonald AP; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Published conference paper: ANNALS OF ONCOLOGY. 2006;17:X144-X154
The biology and treatment of chronic lymphocytic leukemia
Palma M; Kokhaei P; Lundin J; Choudhury A; Mellstedt H; Osterborg A
Review: SEMINARS IN ONCOLOGY. 2006;33(2):S29-S35
Strategies in the management of alemtuzumab-related side effects
Osterborg A; Karlsson C; Lundin J; Kimby E; Mellstedt H
Editorial comment: MEDICAL ONCOLOGY. 2006;23(1):137-139
Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia
Lundin J; Karlsson C; Celsing F
Letter: BLOOD. 2005;105(10):4148-4149
No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome
Lundin J; Kennedy B; Dearden C; Dyer MJS; Österborg A
Meeting abstract: BLOOD. 2004;104(11):277A
Virus reactivation profile as assessed by PCR and serology pattern following first-line alemtuzumab (anti-CD52 monoclonal antibody, Campath®) therapy in patients with B-CLL.
Karlsson C; Dahl H; Linde A; Lundin J; Björkholm M; Mellstedt H; Osterborg A
Meeting abstract: BLOOD. 2004;104(11):689A
T-cell function in patients with B-cell chronic lymphocytic leukemia (B-CLL) following alemtuzumab (Campath®) or fludarabine treatment.
Kiaii S; Mozaffari F; Lundin J; Rezvany R; Chudhury A; Mellstedt H; Osterborg A
Review: CURRENT TREATMENT OPTIONS IN ONCOLOGY. 2004;5(3):203-214
Therapy for mycosis fungoides.
Lundin J; Osterborg A
Thesis / dissertation: 2003
Targeted CD52 therapy in lymphoid malignancies : a clinical and immunological study
Lundin, Jeanette

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2024-2027

Examina och utbildning

Docent, inriktning: Onkologi, Karolinska Institutet, 2010
MEDICINE DOKTORSEXAMEN, Institutionen för onkologi-patologi, Karolinska Institutet, 2003

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI